Premium
CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Author(s) -
Tam C. S. L,
Allan J. N,
Siddiqi T,
Kipps T. J,
Jacobs R,
Opat S,
Barr P. M,
Tedeschi A,
Trentin L,
Bannerji R,
Jackson S,
Kuss B,
Moreno C,
SzaferGlusman E,
Russell K,
Zhou C,
Ninomoto J,
Dean J. P,
Ghia P,
Wierda W. G
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.32_2879
Subject(s) - ighv@ , medicine , venetoclax , gastroenterology , clinical endpoint , chronic lymphocytic leukemia , tumor lysis syndrome , ibrutinib , regimen , oncology , randomized controlled trial , leukemia , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom